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Abstract
Direct reprogramming of one cell type into another without passing through a pluripotent 
state can be promoted by expressing transcription factors necessary during embryonic 
development for the specification of the new cell-type. The transcription factors Pdx1, Ngn3, and 
MafA when expressed together by an adenoviral vector (Ad-PNM) are able to directly reprogram 
Sox9+ cells lining the bile ducts of mice into insulin expressing cells that restore glucose 
homeostasis in diabetic mice.  As an extension of this work, in this research project Ad-PNM was 
administered in vivo to the liver of a non-human primate and also to human pancreatic ductal 
cells in vitro. 
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Introduction
Studies of the direct reprogramming of somatic cells to an insulin-secreting cell-type will 
aid preclinical studies and future clinical translation of both in vivo and ex vivo gene therapy 
approaches for humans with type 1 diabetes. In 2011, approximately 25.8 million people or 8.3% 
of the population within the United States, had diabetes1. The prevalence of diabetes in the United 
States continues to grow every year effecting both children and adults. Diabetes is a disease that 
affects insulin-producing cells, β-cells, which are found in the islets of the pancreas. Insulin is 
needed for the transport of ingested sugars into cells to be broken down into usable energy for 
cellular processes. In type 1 diabetes the immune system destroys pancreatic β-cells resulting in a 
loss of endogenous insulin production and consequently loss of glucose homeostasis. The current 
standard of care for diabetes is to provide exogenous insulin through injection or an insulin-
pump. Close medical care is also needed to successfully control diabetes. In the US depending on 
insurance coverage, these services and prescriptions come with varying out of pocket costs for 
patients. In 2012 the total cost for those diagnosed with diabetes in the United States was roughly 
$245 billion1. 
Adequate medical care and supplies are available in industrialized countries for the proper 
care and treatment of diabetes. In less developed countries where diabetic care is sparse, a 
relatively simple and safe gene therapy approach to rescue or improve blood glucose control 
would make a significant difference for patients. Without proper care, a person with diabetes will 
develop complications. These include but are not limited to high blood pressure, blindness, 
kidney disease, neuropathy, amputation, heart disease and stroke1. When complications arise the 
healthcare burden and risk of premature death also increases. 
Currently, the only option to reach a semi-curative state is islet transplantation. Most of 
these are allogeneic transplants from cadaver pancreas but there are also autologous transplants 
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for pancreatitis patients who have undergone total pancreatectomy. Islets are digested from 
deceased-donor pancreases (or the patient pancreas in the case of autologous transplant for 
pancreatitis) and prepared for infusion through the hepatic portal vein of the patient’s liver. 
Infusing through the hepatic portal vein places the islets in an environment rich in oxygen and 
nutrients by attaching islets to the walls of small veins. One infusion is not always adequate to 
render the patient independent of exogenous insulin. The patient risks requiring repeat 
transplantation depending on how the islets respond after infusion. In the case of allogeneic 
transplants another associated risk is life-long immunosuppression to protect the newly 
introduced islets from the patient's immune system. Allogenic islet transplantation using 
cadaveric donor islets is limited by the lack of organ donors and is currently only widely 
available to patients who cannot sense their hypoglycemia2. Overcoming the lack of islet supply, 
by improving the success of islet transplantation such that fewer islets are necessary per patient, 
or generating alternative sources of insulin producing cells would open this treatment to 
additional patients. 
Insulin producing cells can potentially be made by differentiating embryonic stem cells 
(ESCs) or induced pluripotent stem cells (iPSCs) along the pancreatic lineage3,4. This could 
potentially provide an unlimited cell source that could then be used for transplantation. Another 
potential for transplantation is a cell type that is developmentally related to pancreatic progenitor 
cells that could be directly reprogrammed in vivo or ex vivo into an insulin-secreting cell. 
Reprogramming cells involves providing specific transcription factors to stably change the 
phenotypic identity into a new cell type. When transcription factors in a vector are delivered to 
the cells of interest transient expression of these genes can occur. This can induce non stable 
respecification of the cell type by directly activating target genes. True reprogramming occurs 
when endogenous genes are activated by the vector's transient gene expression and the new cell 
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phenotype is stable after the exogenous genes are lost. 
• Reprogramming is achieved by delivering specific transcription factors into one somatic 
cell type to turn it into a different cell type.
• A gene delivery vector is used to get the transcription factors into the beginning cell type.
• Transient re-specification of cells may occur when gene expression from the vector is still 
present within cells. 
• Stable reprogramming occurs only when the new phenotype of the cell is maintained by 
endogenous gene expression and the vector gene expression is no longer present. 
For a number of years researchers have been attempting to reprogram cells from the liver, an 
endoderm derived organ closely related in embryology to the pancreas, into insulin producing 
cells5,6. Understanding the embryonic development of the liver and pancreas provides perspective 
on the strategies involved with this direct reprogramming.
The liver and pancreas are closely related during embryonic development because they 
both arise from the foregut endoderm epithelium7,8. Patterning signals that result in the ventral 
pancreatic bud and adjacent liver bud gaining separate identities include fibroblast growth factors 
and bone morphogenetic protein signaling from the surrounding mesenchyme and occur at e10 of 
development in the mouse9. Since liver and pancreatic cells arise from common progenitors, it 
has been proposed that the configuration of chromatin in liver cells may remain more accessible 
to pancreatic transcription factors than less related organs10. Both the liver and pancreas also 
contain Sox9 expressing progenitor cells during organogenesis and Sox9+ cells persist in ductal 
regions of both mature organs11. Sox9+ embryonic pancreatic ductal cells differentiate into both 
acinar and endocrine cells of the pancreatic lineage12,13 and Sox9 stimulates proliferation and 
survival of pancreatic progenitors during development14. Sox9 maintains control of the pancreatic 
progenitor pool through its regulation of the expression of the transcription factor Ngn3 which in 
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turn regulates cells fate to be ductal or endocrine15. 
It has been proposed that if at the embryonic stage, the multipotent Sox9+ cells can give 
rise to insulin+ cells, then Sox9+ cells in pancreatic ducts or small bile ducts of the adult liver 
could potentially change their identity by being exposed to pancreatic transcription factors and 
become an insulin-secreting cell type. Extensive research has been done to identify specific 
transcription factors that can reprogram various cell types into a state that secretes insulin. 
This use of exogenous transcription factor expression to change the identity of cells is 
known as direct reprogramming. Perhaps the best example of this is now considered to be 
induced pluripotent stem (iPS) cell derivation16 although examples have now been published from 
many cell types including neurons, cardiomyocytes, hepatocytes and pancreatic cells17. In 2008, 
Zhou, Q., et al. reported the in vivo direct reprogramming of pancreatic exocrine cells into 
insulin-secreting cells. Using a mouse model, this group reprogrammed exocrine cells into β-like-
cells that secrete insulin by using a combination of three separate CMV promoter driven 
adenovirus vectors encoding Pdx1, Ngn3, and MafA (PNM)18. The identification of the PNM 
combination was made after screening transcription factors with specific cell type expression 
profiles in the embryonic pancreas19. Pdx1 is required during pancreas development and later for 
proper β-cell function. Ngn3's transient expression during development is needed for the 
formation of endocrine progenitors and MafA is required for the correct expression of insulin in 
mature β-cells20–22. 
Figure 1. Ad-PNM vector construct. Adapted from23. 
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The design of this current study is based on previously published research from the Dutton 
laboratory describing the in vivo and in vitro use of Ad-PNM. The conversion of hepatic cells into 
insulin expressing cells had been pursued by the overexpression of developmentally relevant 
transcription factors23–26 culminating in the generation of glucose-responsive, insulin-secreting 
cells by directly reprogramming hepatic bile duct cells in diabetic mice23,25. Using three 
transcription factors Pdx1, Ngn3 and MafA in a poly-cistronic adenovirus vector (Ad-PNM) 
allows high levels of simultaneous protein expression (Figure 1). The intravenous injection of 
Ad-PNM in immune deficient, diabetic NOD SCID mice23 and more recently in immune 
competent, diabetic wild-type mice has resulted in long-term remission of diabetes. The extended 
restoration of blood glucose control in these animals is achieved by the stable conversion of 
Sox9+ small bile duct cells into insulin-secreting ducts following transient expression of Ad-
PNM. The de novo insulin-expressing ducts persist after the exogenous Ad-PNM vector has 
decayed and is considered a permanent in vivo direct reprogramming. Although the ductal cells 
are clearly not β-cells, their high degree of stable reprogramming and ability to function as 
replacement insulin producing cells makes them a very attractive proposition for curing type 1 
diabetes. The next direction for this research is to test the in vivo administration of Ad-PNM in a 
large animal model and the in vitro reprogramming efficiency of Ad-PNM using human cells.
Two hypotheses were tested: Specific aim 1 is whether portal vein infusion of Ad-PNM in 
a non-human primate (NHP) can reprogram Sox9+ bile duct cells into insulin-secreting cells to 
rescue type 1 diabetes in this large animal model. Also, since human bile duct cells and normal 
liver tissue are not readily available, another human tissue source containing Sox9+ cells was 
been utilized for the in vitro research. Pancreatic ducts are an unused waste tissue after islet 
isolation procedures and are readily available through the University of Minnesota Medical 
Center. Specific aim 2 is to isolate, culture, and test human Sox9+ pancreatic ductal cells for their 
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reprogramming capability with administration of Ad-PNM. 
Using a type 1 diabetic, large animal model for the infusion of Ad-PNM is attractive since 
rhesus macaques are more closely related evolutionarily to humans than mice.  This model may 
provide a better understanding of the potential therapeutic effect Ad-PNM in humans. Using a 
nonhuman primate model is also necessary for the collection of preclinical data for the safety and 
efficacy of Ad-PNM before clinical trials in humans can be initiated.
Previously the Dutton laboratory had conducted a single test of Ad-PNM administration 
into the liver of an immunosuppressed type 2 diabetic cynomolgus macaque, with a 50 day post-
infusion follow up. Following administration of Ad-PNM by hepatic portal vein catheter, the 
animal showed no adverse effects and Ad-PNM viral gene expression was detected for at least 9 
days post infusion (Figure 2). Genomic DNA analysis indicated the Ad-PNM vector was present 
for at least 9 days after infusion indicating successful delivery of the Ad-PNM vector to the liver. 
Figure 2. Type 2 diabetic NHP mRNA expression. 
6
The administration of Ad-PNM by infusion through the hepatic portal vein is advantageous 
to reach the small bile duct cells and is a method in common use for islet transplantation’s in 
humans and NHP's. The hepatic portal vein is unlike other veins in the body, since it does not 
drain back to the heart. Instead, the hepatic portal vein provides a significant amount of the liver’s 
blood flow along with the hepatic artery. Blood flows from the hepatic portal vein and artery, 
located at the portal triad of liver lobules, through sinusoids flanking hepatocytes to the central 
vein, located in the middle of the lobule. It is the central vein that drains deoxygenated blood 
from the liver and guides it back to the heart. All lobes of the liver are accessed by the branching 
of the hepatic portal vein27. 
The branching pattern of the hepatic portal vein is mirrored by the bile ducts and the 
hepatic portal vein supplies oxygenated blood to the bile ducts. The close proximity between the 
hepatic portal vein and bile duct allows for potentially relatively direct administration of Ad-
PNM through a hepatic portal vein catheter to transduce Sox9+ small bile duct cells. 
Previous studies have been conducted with NHP hepatic artery or portal vein infusion of 
adenoviral vectors to test the safety and efficacy of gene delivery. Safety and efficacy were tested 
with adenoviral infusion into NHP liver during a dose response trial. Liver function was 
monitored with AST and ALT assays as well as tissue sectioning the liver to observe any 
detectable morphological damage.  The “maximum tolerated dose of an adenovirus vector with 
significant gene transfer” in rhesus macaques was 5 x 10^12 particles/kg28. How the adenoviral 
vector would spread throughout the NHP body was a concern so biodistribution assays were 
conducted where DNA was collected from the blood, bone marrow, colon, duodenum, heart, 
liver, kidney, lung, prostate, spleen lymph node, and testes tissues to test for adenovirus 
incorporation. Six hours after vector administration the different tissues were harvested and 
analyzed to measure the number of vector copies per microgram of chromosomal DNA. High 
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levels of vector copies were detected in the spleen and bone marrow but the highest level was in 
the liver. Safety was assessed through cytokine analysis and monitoring of AST and ALT levels 
of the liver29. Other groups were especially concerned with the possibility of the adenoviral vector 
disseminating to the gonads and expressing genes in germ cells30.
 The idea to utilize pancreatic ductal cells as a cell source to reprogram into β-cells is not 
new. In vivo studies in mice have revealed β-cell neogenesis can arise from ductal cells after 
pancreatic injury. Partial duct ligation (PDL) in adult mice activated Ngn3+ progenitor cells that 
can differentiate into β-cells ex vivo and in vivo31.
Another group of researchers used a different pancreatic injury model to observe which 
cells contributed to β-cell regeneration. To selectively ablate tissues, mice expressing diphtheria 
toxin receptor (DTR) at the Rosa26 locus were made to express Cre in the acinar and endocrine 
tissues of the pancreas. Upon exposure to diphtheria toxin, acinar and endocrine cells were killed 
leaving the pancreatic ductal tree intact. The surviving cells in the ducts contributed to the 
regeneration of the endocrine and acinar cells by recapitulating embryonic pancreatic 
development32.
After β-cell regeneration was observed after injury to the pancreas, studies utilizing genetic 
manipulation in mice were performed to understand this phenomena. Lineage tracing assays 
labeling pancreatic duct cells demonstrated the developmental relatedness between endocrine and 
ductal tissues. Precursor cells of acinar, duct, and endocrine lineages are Hnf1β+ found in the 
trunk compartment of the early branching pancreas. When the embryonic duct epithelium is 
formed the Hnf1β+ cells give rise to ductal and endocrine lineages but not acinar. The Hnf1β+ 
cells fate is further restricted by the end of gestation since they do not significantly contribute to 
acinar or endocrine cell populations during neonatal growth nor during the regenerative setting 
following injury to the pancreas33. Solar et al. suggests a restricted plasticity once the ductal 
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epithelium differentiates. 
Controversy has arisen over whether adult pancreatic ducts having facultative β-cell 
progenitors or not. Many researchers rely on Ngn3 expression as evidence of β-cell neogenesis in 
adult mice since it is a key determinant of endocrine neogenesis in the pancreas during 
embryogenesis34. However, recent reports show Ngn3 expression also occurs in fully-developed 
β-cells35 making lineage tracing research using this marker to show beta cell neogenesis from duct 
cells less certain.
During human islet transplantation the tissue remaining after islet isolation consists of 
mainly connective tissue and pancreatic ducts with residual exocrine tissue and islets that were 
not reclaimed. In immunohistochemical analysis of human donor pancreata it was observed that 
β-cells with a diameter less than 20μm were located in or along pancreatic ducts. It appeared as 
though they budded from the ducts36. This observation of β-cell neogenesis from the ducts is 
similar to the studies in mice. 
Numerous groups have been utilizing the tissue left at the end of human islet isolation for 
pancreatic duct research. Isolating the ductal cells from this tissue has been accomplished by 
using FACS, MACS or both to sort for CK19+ or CD133+ cells37–39. Others have utilized culture 
conditions to isolate, expand, and promote insulin expression in ductal cells38,40. Some groups 
have expanded the ductal cell population using different extracellular matrices and then 
reprogrammed the cells with adenoviral vectors encoding transcription factors favorable for 
transition to a pancreactic endocrine lineage39,41. Lee et al employed Neurog3, Pdx1, MafA, and 
Pax6 over-expression in duct cells cultured on matrigel with an extended maturation culture 
period. Swales et al utilized tissue-culture treated plastic plates for culturing human pancreactic 
ductal cells. Their aim was to transfect the cells with adenoviral vectors encoding Ngn3 and Myt1 
and then profile the mRNA transcripts for endocrine genes. All of these studies reported cell 
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populations with various levels of insulin secretion and glucose responsiveness. 
It is estimated the human pancreas has between one and two million islets. However, it is 
difficult to isolate adequate quantities consistently to use for clinical transplantation42. This 
current research using human pancreatic ductal cells was undertaken to develop a clinically 
translational autologous cell product for chronic pancreatitis patients who have undergone total 
pancreatectomy with islet autotransplant (TP-IAT) but will need β-cell replacement when their 
autologous islet transplant fails. This work was performed in collaboration with Dr. Melena 
Bellin, a pediatric endocrinologist at the University of Minnesota's Medical Center. Dr Bellin and 
her team generously supplied samples and scientific knowledge to this research. Total 
pancreatectomy (TP) is performed for patients with chronic pancreatitis to relieve pain and is 
followed by islet autotransplant (IAT) to prevent or minimize post-surgical diabetes by 
preserving β-cell function43. 
Banking pancreatic ductal cells would be beneficial for patients undergoing TP-IAT 
because this would save an autologous cell source for potential future use. Once direct 
reprogramming of pancreatic ductal cells into a β-cell state is achieved with high efficiency, 
patients who develop exogenous insulin dependence could receive another autologous transplant 
of insulin-secreting cells. Work on expanding and reprogramming ductal cells from allogeneic 
donor pancreas to a β-cell-like phenotype would also provide an additional source of insulin 
expressing cells for transplantation not only for pancreatitis patients but also those living with 
type 1 diabetes.
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Methods
Purification of Ad-PNM
The Ad-PNM vector is amplified in an Ad-293 cells and must to be purified after 
amplification. Purification began by thawing the -80°C cell/media mixture within 50ml conical 
tubes at room temperature for 1 hour then in a 37°C water bath until all ice crystals disappeared. 
The tubes were then subjected to six rounds of thaw, vortex, and freeze in a dry-ice, ethanol bath 
to lyse the cells and release the Ad-PNM virus particles. The cell/virus suspension was then 
centrifuged at 3000rpm for 45 minutes to separate the cell debris from the adenovirus that 
remains in the supernatant. The supernatant containing the virus was poured into a vacuum filter 
unit. The flow-through was collected into a new 50ml conical tube and kept on wet ice while 
Cesium Chloride (CsCl) gradients were prepared. 
The gradient consisted of 6mL 4M CsCl at the bottom, 6mL 2.2M CsCl in the middle, and 
about 25mL of the viral suspension on the top in a 38.5mL open-top polyclear centrifuge tube. 
The CsCl gradients with viral suspensions were centrifuged at 27,000rpm at 4°C overnight. A 
white band containing the Ad-PNM was observed in the middle of the tube. The top yellow and 
pink supernatants were aspirated and the white bands were removed with a 5ml pipette and 
placed into a new 50ml conical tube. An equal amount of saturated CsCl was added to the Ad-
PNM suspension and divided equally among new open-top polyclear centrifuge tubes. Next, 
4.5mL 4M and 4.5mL 2.2M CsCl were layered on top of 8mL of the saturated CsCl/Ad-PNM 
mixture to create a gradient in 17mL open-top poly clear centrifuge tube. Before loading the 
ultra-centrifuge, the tubes were weighed and paired for balancing. Centrifugation at 27,000rpm 
occurred for 3 hours at 4°C.  Two white bands in the middle of the tubes were observed after 
centrifuging. The lower white band was removed with a 1000 microlitre pipette and placed in a 
new 15ml conical tube. This stock of Ad-PNM was considered “Hi” titer. The rest of the band 
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and the second white band was also removed and was considered “Low” titer. The tubes were 
kept on wet ice until the dialysis components were prepared.
 To remove remaining CsCl in suspension in the Ad-PNM stock, the solution was dialysed. 
Dialysis tubing was prepared by boiling in a 2% sodium bicarbonate solution for 10 minutes, 
rinsed twice with sterile water, and then boiled in 1mM EDTA solution for 10 minutes, cooled to 
4°C and stored in 50% ethanol. The dialysis tubes were rinsed inside and out with sterile water 
then knots were tied into one end. The Hi and Low titer Ad-PNM were kept separate and pipetted 
into their respective dialysis tubes and another knot was tied into the other end. Plastic clips were 
placed on the inner side of the knots. Filled dialysis tubes were kept on wet ice until placed into 
1L of PBS 5% glycerol solution with magnetic stir bar in a 4°C cold room. After 1 hour, the tubes 
were moved into a 2L PBS 5% glycerol solution and kept their overnight. The next day, the tubes 
were moved into a new 1L PBS 5% glycerol solution and incubated for 1 hour. 
The purified Ad-PNM was then removed from the dialysis tubes and stored in aliquots. An 
insulin syringe was used to poke a hole in the dialysis tubes and remove the Ad-PNM solution. 
Various volumes were aliquoted into Eppendorf or PCR tubes and kept on wet ice. The tubes 
were centrifuged, placed on dry-ice to freeze, and stored at -80°C.
Titering of Ad-PNM
After purification of Ad-PNM, the adenovirus was titered using the Adeno-X Rapid Titer 
Kit46. Ad-293 cells were plated at a density of 2.5 x 10^5 cells per well of a 24-well plate in high-
glucose DMEM 10% FBS with antibiotics. The next day, Ad-PNM batches were diluted in media 
from 10^-2 to 10^-6 in duplicate. The media was aspirated from the wells and replaced with 
500µl of Ad-PNM dilution. Plates were incubated at 37°C for 48 hours. After two days of Ad-
PNM infection, the media was aspirated and the cells were allowed to dry in the BSL2 hood for 5 
minutes. The cells were fixed by gently adding 500µl of ice-cold 100% methanol to each well and 
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incubated at -20°C for 10 minutes. The methanol was aspirated and the wells were rinsed three 
times with 500µl of PBS + 1% BSA. The final rinse was aspirated then Mouse Anti-Hexon 
Antibody diluted 1:1000 in PBS + 1% BSA was added to each well and incubated for 1 hour at 
room temperature. The primary antibody was aspirated and the wells rinsed three times with PBS 
+ 1% BSA. The final rinse was aspirated and Horse Anti-Mouse antibody (HRP conjugate) 
diluted 1:500 in PBS + 1% BSA was added to each well and incubated for 1 hour at room 
temperature. During this incubation step, the DAB working solution was made by diluting 10X 
DAB substrate 1:10 in 1X stable peroxidase buffer and was allowed to come to room 
temperature. After incubation of the secondary antibody, the wells were aspirated and rinsed three 
times with PBS + 1% BSA. The final rinse was aspirated then the DAB working solution was 
added to each well and incubated at room temperature for 10 minutes. The DAB working solution 
was aspirated and PBS was added to each well. Each virus dilution was visualized at an objective 
of 20x on an inverted microscope to determine which dilution had 5-50 cells positively stained 
for the Hexon protein. Pictures were taken of three fields in each well of the dilution that fit the 
criteria. Counts and calculations were made to determine the titer (infectious units per milliliter) 
of Ad-PNM. 
ifu/ml = (cell/field) x (fields/well) / (volume of Ad-PNM) x (dilution factor)
Functional assay of Ad-PNM
To determine the infection efficiency and function of different batches of Ad-PNM 
adenovius preparations we used, AR42J-B13 cells (B13s), a rat pancreatic exocrine cell line44. 
Cells were cultured in low-glucose DMEM, 10% FBS at 37°C in 5% CO2 and the media was 
replaced every 2 days. For Ad-PNM infection 50,000 B13 cells were plated per 9.6 cm2 well of a 
6-well tissue-culture treated plate Cells were allowed to attach overnight and the media changed 
before virus infection. A virus dilution was made by adding a 1 µl aliquot of Ad-PNM adenovirus 
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preparation into 1ml low-glucose DMEM, 10% FBS. 100 µl, 50 µl, and 10 µl of the diluted virus 
were added to 3 separate wells for the infection of B13 cells overnight. A well of uninfected B13 
cells was also plated to use as a negative control.  Following the night of infection, the media in 
the wells was replaced. On the third day after infection, the cells were fixed in preparation for 
immunohistochemistry. Following antibody detection the cells in at least three fields per well 
were analyzed at 200x magnification and cells expressing Pdx1 and insulin were counted to 
calculate the degree of reprogramming.
Preparation of tissue for immunohistochemistry and histology
Whole pieces of tissue were fixed overnight at 4°C in 10% formalin. The formalin was 
then replaced with a 30% w/v sucrose solution and the tissue was stored in this solution at 4°C 
until embedding in Optimal Cutting Temperature compound (OCT). OCT blocks were stored at 
-80oC. 9µm thick tissue sections were cut with a Leica CM3050 S cryostat at -20oC, mounted on 
Superfrost Plus microscope slides and stored at -80°. Slides were prepared for 
immunohistochemistry by removing them from  -80°C and allowing the slides to return to room 
temperature. The OCT was washed from the tissue sections by immersing the sides in PBS-T for 
5 minutes. Slides were removed from the PBST bath and dabbed on paper towels to remove 
excess liquid then placed in a dark slide box. If permeablization was required, 100-250 µl of PBS, 
1% BSA 1% Tween 20 solution was pipetted onto the slides which were then overlaid with 
parafilm. for 10 minutes at room temperature. All slides were treated to reduce nonspecific 
antibody binding with a blocking solution (PBS-T 1% BSA) for 15 minutes, covered with 
parafilm. Primary antibodies were diluted in blocking solution, pipetted onto the slides, and 
covered with parafilm to incubate overnight at 4°C. The following day, the slides were washed in 
a PBS-T bath for 10 minutes, before incubation with secondary antibodies diluted in blocking 
solution at room temperature for one hour. After incubation with the secondary antibody, the 
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slides were washed in PBS-T for 10 minutes, before adding DAPI (10mg/ml stock) diluted 1 in 
1000 in PBS-T was pipetted on to the slides and incubated at room temperature for 3 minutes. 
The slides were washed again in PBS-T for 5 minutes, before mounting with Immu-Mount 
(Thermo Scientific) and a cover-slip. The slides were sealed with clear nail polish painted along 
the edges of the cover-slip.
Fixing Cells and Immunocytochemistry
Media was removed from cells in culture and the cells fixed for 10 minutes at room 
temperature by immersion in 10% formalin. The formalin was aspirated and the wells were 
washed three times over 15 minutes with PBS-T. 2ml of fresh PBS-T was then placed in each 
well and the plates were stored at 4°C. 
Cells were permeablized for 10 minutes with PBS-T 1% BSA 1% Tween 20. Nonspecific 
antibody binding was reduced by blocking for 30 minutes with a blocking solution (PBS-T 1% 
BSA). Primary antibodies were diluted in blocking solution and incubated for one hour at room 
temperature or overnight at 4°C. After incubation, the wells were washed three times with PBST 
and the secondary antibody diluted in blocking solution was incubated in wells for one hour at 
room temperature or overnight at 4°C. After incubation the wells were washed three times with 
PBST and a 1 in 1000 dilution of DAPI (10mg/ml stock) was added to each well. 
Table 1. Primary antibodies and dilutions.
Primary Antibody Dilution
Millipore Anti-Pdx1 rabbit 1:2000
Sigma Anti-Insulin guinea pig 1:250
Millipore Anti-Sox9 rabbit 1:1000
Dako Anti-Cytokeratin 19 mouse 1:500
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Table 2. Secondary antibodies and dilutions.
Secondary Antibody Dilution
Alexa Fluor 488 goat anti-rabbit 1:1000
Alexa Fluor 555 donkey anti-rabbit 1:500
Alexa Fluor 555 donkey anti-mouse 1:500
Alexa Fluor 555 donkey anti-guinea pig 1:500
Rhodamine Concanavalin A 1:100
Alexa Fluor 647 donkey anti-mouse 1:1000
Plaque Forming Units assay
To determine the plaque forming units of the Ad-PNM preparation administered to type 1 
diabetic NHP, we performed a PFU assay. Ad-293 cells were thawed and cultured in high-
glucose DMEM, 10% FBS with 1x penicillin.streptomycin. Once the cells reached 80% 
confluency, they were passaged with 0.25% Tyrpsin and replated at a density of 5 x 105 cells per 
well of 6-well tissue culture plates and incubated overnight at 37°C. The next day, Ad-PNM was 
diluted from 10-2 to 10-6  in 1 ml volumes of media. Each dilution was carried out in duplicate. 
The media in the 6-well plates with Ad-293 cells was aspirated and each well was replaced with 
the different 1 ml Ad-PNM dilutions. Two wells were left with media, no Ad-PNM, as a negative 
control. To infect the Ad-293 cells with Ad-PNM, the 6-well plates were incubated for 2 hours at 
37°C. Meanwhile, an autoclaved solution of 2% agarose in PBS was melted in the microwave, 
allowed to cool to about 45°C and maintained at this temperature through incubation in a water 
bath. Media was equilibrated to 37°C. Equal volumes of media and melted agarose were added 
together and mixed well. The media containing the different dilutions of Ad-PNM was aspirated 
out of the 6-well plates and 3 ml of agarose/media mix was gently pipetted into each well to 
overlay the Ad-293 cells. The 6-well plates were tilted to ensure the agarose completely covered 
the bottom of the wells. The plates were incubated at 37°C45.
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NHP Care
Care for NHP's was provided by the PCRC in accordance with an approved IACUC 
protocol. Collaboration with Dr. Melanie L. Graham, an expert in diabetes research with non-
human primates, and her team allowed for innovative and clinically relevant research47–49. 
Training and surgical procedures to implant the hepatic portal vein catheter occurred at the PCRC 
under the supervision of Dr. Graham. The induction of diabetes was made through an STZ 
injection48. The PCRC conducted the infusion of Ad-PNM and collection of liver needle biopsies 
throughout the study. The needle biopsies were used for PCR analysis of the expression of PNM. 
All laboratory screening panels for the type 1 and 2 diabetic NHP's were collected and analyzed 
by the PCRC (Appendix).
NHP Liver Biopsy Processing for RNA Extraction
Non-human primate liver biopsies were collected with a 20 gauge needle and transferred 
into 500µl of Trizol Reagent and immediately frozen at -20°C by staff at the University of 
Minnesota's Preclinical Research Center (PCRC).The samples were transferred to the Stem Cell 
Institute, thawed, vortexed, and homogenized with a tissue grinder pestle. The mixture was then 
centrifuged at 13,000 x g for 1 minute and the supernatant was removed from the remaining 
particulate pellet and put into a new RNase-free tube for RNA purification.
Cell Processing for RNA Extraction 
RNA from cell monolayers was extracted by lysing adherent cells in culture plates with 
Trizol Reagent through repeated pipetting and mixing within the wells. The cell lysate was then 
transferred to an RNase-free tube and centrifuged for 1 minute at 13,000 x g. The supernatant was 
separated from particulates in the bottom of the tube by transfer into a new RNase-free tube. 
RNA Extraction
RNA purification involved adding one volume ethanol to one volume of tissue or cell 
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sample homogenate in Trizol Reagent. The ethanol/Trizol mixture was then loaded into a Zymo-
Spin IIC column placed in a collection tube and centrifuged for 1 minute at 13,000 x g to bind the 
RNA to the column. The flow-through was discarded, and the column was then washed with 
RNA wash buffer and centrifuged for 30 seconds. Flow-through was discarded and then a DNase 
I Reaction Mix was added to the column and incubated at room temperature for 15 minutes. 
Following incubation, the column was centrifuged for 30 seconds and then Direct-zol RNA 
PreWash was added and centrifuged for 1 minute. Then the RNA wash buffer was added to the 
column and centrifuged for 1 minute. The RNA in the column was then eluted into a new RNase-
free tube by centrifuging 35µl of DNase/RNase-Free water through the column for 1 minute.  
(Direct-zol RNA MiniPrep). Samples were then analyzed using a NanoDrop Lite 
Spectrophotometer (Thermo Scientific) to determine concentration of RNA in the sample.
A second DNase treatment was implemented to ensure the samples were DNA-free. In a 
RNase/DNase-free PCR tube, 2.2ug of purified RNA, DNase, 10x DNase buffer and DEPC water 
was added and then incubated in a BioRad T100 Thermal cycler at 37°C for 45 minutes. Once the 
DNase reaction was complete, the tubes were placed in the -80°C freezer and stored until further 
use. 
RNA Quality assay
To test the quality of RNA samples, a bleach ethidium bromide gel was run. A 1.5% 
agarose 1.15% bleach gel was made with Tris-acetate EDTA (TAE, Sigma Aldrich) buffer.  RNA 
samples were thawed, vortexed, and 2ug of the sample put into a new PCR tube. An equal 
volume of, denaturing loading dye (Ambion #8546G) was added. The wells of the bleach gel 
were loaded with the RNA samples.. Gel electrophoresis was run at 100V for 20 minutes. 
DNase assay
To ensure previous DNasing steps worked, RNA samples were tested before cDNA 
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synthesis by using the RNA as a template in a PCR reaction. If no DNA is present the RNA 
template should not generate a product in this test. All experimental samples as well as positive 
and negative control reactions were amplified in a Thermocycler for 35 cycles at an annealing 
temperature of 60°C.  Samples were then loaded into wells of a 1.5% agarose gel and run at 110V 
for 25 minutes. Pictures of the gel were taken with a Gel Logic 212 Pro.
cDNA Synthesis
cDNA was synthesized from RNA samples using SuperScript III First-Strand Synthesis 
System (Life Technologies). 1µg RNA, random hexamers and dNTPs in a total volume of 
13micorlitres were incubated for 5 minutes at 65°C to denature the RNA. Next the cDNA 
synthesis mix was added to each sample and incubated at room temperature for 10 minutes to 
anneal the random hexamers to the RNA template. Then, the samples were incubated at 50°C for 
50 minutes to enable the Superscript III Reverse Transcriptase to synthesize cDNA. The 
incubation was terminated at 85°C for 5 minutes and then cooled to 4°C. cDNA samples were 
stored at -20°C until ready for PCR amplification. 
Primer Reconstitution
Primers were purchased from IDT and reconstituted in DEPC water as 50µm stock 
solutions. The reconstituted primer was heated in a dry bath for 5 minutes at 65°C to ensure the 
primer was completely resuspended. The primers were then diluted to 10 µm working stock 
solutions. Stock primers and primer aliquots were stored at -20°C.
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Table 3. Primers and sequences.
Gene Name Sequence, 5'-3' DNA Bases Melting 
Temperature °C
Reference #
mPdx1-
Forward
CCG GAC ATC TCC CCA 
TAC GAA GT
23 60.3 126213555
mPdx1-
Reverse
CGC ACA ATC TTG CTC 
CGG CTC TT
23 62.1 126213548
mMafA-
Forward
ATC ATC ACT CTG CCC 
ACC AT
20 56.2 126213551
mMafA-
Reverse
AGT CGG ATG ACC TCC 
TCC TT
20 57.4 126213552
mNgn3-
Forward
CCG GAT GAC GCC AAA 
CTT ACA
21 57.7 126213553
mNgn3-
Reverse
ACA CCA GTG CTC CCG 
GGA G
19 62.2 126213554
hGapdh-
Forward
CCA AAA GGG TCA TCA 
TCT CTG C
22 55.9 126213546
hGapdh-
Reverse
ACT CCT TCC ACG ATA 
CCA AAG T
22 55.8 126213547
hAlbumin-
Forward
TGC TTG AAT GTG CTG 
ATG ACA GGG
24 59.7 126213541
hAlbumin-
Reverse
AAG GCA AGT CAG CAG 
GCA TCT CAT C
25 61.3 126213542
hCk19-
Forward
CGA CTA CAG CCA CTA 
CTA CAC GA
23 57.7 126213543
hCk19-
Reverse 159
CTC ATG CGC AGA GCC 
TGT
18 58.1 126213545
hCK19-
Reverse 307
GCC CCT CAG CGT ACT 
GAT TT
20 57.4 126213544
PCR
PCR amplification was performed using synthesized cDNA as template and primers for the 
genes of interest in a BioRad TC-100 Thermal Cycler for 30-38 cycles, and an annealing 
temperature of 60°C. Once PCR amplification was complete, the sample were centrifuged and 
loaded into a 1.5% agarose, ethidium bromide, 1x TAE gel for electrophoresis at 110V for 25 
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minutes. A 1kb ladder was also loaded into the gel.
TP-IAT procedure
A description of the TP-IAT procedure can be found in other publications50,51.The 
University of Minnesota Molecular and cellular therapeutics GMP facility performed the islet 
isolation and purification procedure52,53.
Tissue Digestion
Human pancreas tissue, following the islet isolation, was provided in UW solution54for 
preservation. Tissue processing was then performed in the SCI in a BSL2 hood under sterile 
conditions. Most of the UW solution was aspirated from the 50ml conical tube and the tissue 
transferred to a 10cm dish. The sample was visually assessed for any undesired contents such as 
sutures, staples, blood clots, vessels, and hard fibrotic pieces. Once these contaminates were 
removed, the tissue was manually cut up with a scalpel and forceps in preparation for tissue 
digestion. The sample was placed in a 50ml conical tube and 40ml of DMEM 10%FBS added for 
five minutes remove lower density debris away from the sample. The media was aspirated and 
50ml of EGTA dissociation buffer (500µl 10mM HEPES pH 7.4, 250µl 5mM KCl, 250µl 5mM 
glucose, 250µl gentamicin, 50µl 0.5mM EGTA, and 48mL PBS)  prewarmed to 37°C was added 
to the sample. The EGTA buffer and sample were incubated for 20 minutes in a 37°C water bath. 
After centrifuging the sample at 1000rpm for 5 minutes and aspirating the EGTA buffer, 50ml of 
a digestion buffer containing DMEM 5% FBS, 83.3 mg/ml collagenase type II and 66.7 mg/ml 
hylauronidase was added to the sample. During a 40 minute incubation in a 37°C water bath the 
digestion buffer was pipetted to help break apart the tissue. 50 units/ml of dispase was then added 
to the digestion buffer and incubated with pipetting for another 30-60minutes depending on the 
consistency of the tissue. The sample was then washed three times with 50ml DMEM 10%FBS. 
To remove large undigested pieces of human pancreas, the sample was passed through a 100 µm 
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cell strainer and the cell flow through collected. and cultured overnight in an ultra-low attachment 
10cm dish with DMEM 10% FBS, 1 x Pen/Strep, 1x Anti-Anti, and units Gentamicin.
Culture Clean-up
The following day the sample is inspected for aggregation under the microscope. If only a 
single cell suspension exists, the sample was over digested and will be kept in suspension DMEM 
10% FBS for an addition night. When aggregates were present procedures for epithelial ball 
isolation were initiated. The sample in suspension was collected and passed through a 37 µm 
reversible cell strainer to remove the single cells. The strainer was then flipped into a new 50ml 
conical tube and the aggregates were back washed into suspension with Keratinocyte serum-free 
media (KSFM-Life Technologies) and plated in an ultra-low attachment 10cm dish. The 
aggregates were left in suspension and cultured in KSFM for 7-10 days with occasional straining 
with a 37 µm reversible cell strainer to remove the single cells or fibroblasts until distinct clear 
epithelial balls were present. 
Adherent culture of Epithelial cell aggregates
Epithelial cell aggregates were cultured on a plate coated in dry collagen type I, (Corning 
BioCoat Cellware) at 37°C and in 5% CO2 in KSFM media or DMEM + 10% FBS. 
Reprogramming with Ad-PNM 
BioCoat plates were used the Ad-PNM infection assay. The epithelial aggregates were 
divided to make two sub-populations. The infected and uninfected groups were then split 20/80 
and plated onto BioCoat plates. The 20% populations for infected and uninfected were used for 
IHC whereas the 80% populations were for RNA extraction.. BioCoat wells for Ad-PNM 
infection received 1ml of a virus solution made up of 2ml DMEM 10% FBS and a 1.1 µl aliquot 
of a specific Ad-PNM batch. Uninfected wells received 1ml of DMEM media only. After 
overnight infection, the wells were aspirated and 2ml of fresh media were added. On the third day 
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the 20% wells were fixed in preparation for IHC and the 80% wells were used for RNA 
extraction.
Expansion of Epithelial Balls
Expansion of the epithelial cells was tested by plating the aggregates on BioCoat plates or 
in collagen type I. BioCoat plates allowed the cell to adhere and form monolayer patches of 
epithelial cells. Plating in collagen type I involved preparing tissue-culture plates with a layer of a 
collagen solution made up of 8 parts type I collagen (4 mg/ml):1 part Williams E 10x media:1 
part 0.34M NaOH. The plate was then incubated for 30minutes to set the collagen in a gel-like 
state. The epithelial cells in suspension were then added on top of the collagen and allowed to 
attach for two days before aspirating the media and overlaying the well with another 8:1:1 
collagen type I solution. This collagen sandwich was incubated for at least 30 minutes before 2ml 
of KSFM media was added. Media changes were made once a week. 
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Results
Functional assay of Ad-PNM
The different batches of Ad-PNM were tested for their functionality on AR42J B13 cells. 
The efficiency of each Ad-PNM batch to reprogram B13 cells to express Pdx1 and insulin was 
visualized by immunocytochemistry. Uninfected B13 cells were used as a negative control 
(Figure 3A). Figure 3A shows representative results for Ad-PNM batches A2 through A12 for 
Pdx1, Insulin, and DAPI. The functional efficiency to reprogram B13 cells was quantified by 
counting the number of Pdx1+ cells, number of Pdx1+/Ins+ cells and the total number of cells 
(DAPI+)  in at least three different fields at a 200x magnification. The mean percentage of Pdx1+ 
and Pdx1+/Ins+ cells is shown in (Figure 3B). B13 cells with high Pdx1 expression tend not to 
express insulin as seen in A11 Ad-PNM (Figure 3A) as well as expression percentage (Figure 
3B). Insulin seems to be expressed in B13 cells with levels of Pdx1 protein expression such as A8 
Ad-PNM in Figure 3A & B. 
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Figure 3A. Ad-PNM infection functional assay. Each batch of Ad-PNM (A2-A12) was tested for 
its functionality by plating 50,000 B13 cells per 9.6 cm2. Each Ad-PNM was tested in duplicate, 
incubated for three days and then fixed for immunocytochemistry. Wells of uninfected B13 cells 
were used as a negative control. All wells were tested for expression of Ins (red) and Pdx1 
(green) with DAPI (blue). All pictures were taken with an inverted microscope at 200x, the scale 
bar is 100 µm.
Figure 3B. Percent of B13 cells Pdx1+ and Pdx1+/Ins+ for Ad-PNM batches A2 through A12. At  
least three fields were counted from 200x magnification similar to those in Figure 3A.
Ad-PNM titer assay
After the purification of Ad-PNM batches, the viruses were titered to determine the number 
of infectious units per milliliter. The assay titers were calculated for each batch of Ad-PNM 
(Table 4). Ad-PNM batches with higher titers did not always respecifiy B13 cells into expressing 
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insulin (A6 Ad-PNM in Table 4, Figures 3A & B). 
Table 4. Ad-PNM titers.
Ad-PNM Batch Titer (ifu/ml)
A2 1.0 x 10^11
A3 1.18 x 10^10
A4 1.2 x 10^11
A5 1.7 x 10^10
A6 1.3 x 10^11
A7 5.9 x 10^10
A8 3.26 x 10^10
A9 8.03 x 10^10
A10 9.59 x 10^9
A11 1.41 x 10^11
A12 1.97 x 10^10
MM 4.14 x 10^10
JI 6.6 x 10^11
JII 3.68 x 10^11
R1 1.0 x 10^12
Functional assay of diluted Ad-PNM
The variation in the amount of Pdx1 and insulin expression in the different batches of Ad-
PNM lead us to test dilution assays of the virus batches on B13 cells.  A11 Ad-PNM was tested at 
three different dilutions to see if reprogramming improved with less virus exposure. In Figure 4A 
immunohistochemistry of cells infected with different titers of A11 Ad-PNM had varied 
fluorescent intensity of Pdx1 expression. When half the original titer was used to infect B13 cells 
about the same percentage of cells were Pdx1+ as with the full titer virus (Figure 4B). An 
increased percentages of Pdx1+ cells also expressed insulin when one-tenth of the original titer of 
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A11 was used on B13 cells (Figure 4B).
Figure 4A. A11 Ad-PNM infection dilution assay. Dilution assays were performed on the various 
batches of Ad-PNM to see if there was an optimal titer for reprogramming B13 cells. Scale bar is  
100 µm.
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Figure 4B. Percent of B13 cells Pdx1+ and Pdx1+/Ins+ for A11 Ad-PNM dilutions. At least 
three fields were counted from 200x magnification fields similar to those in Figure 4A.
Functional assay of Ad-PNM for NHP infusion
Based on the Ad-PNM functional assays, combinations of the batches were made to infuse 
into the portal vein of diabetic NHP's.  The Ad-PNM infused in the type 2 diabetic NHP was 
composed of JI, JII, and A2 and will be referred to as R1. The type 1 diabetic NHP was infused 
with Ad-PNM made up of A7 and A8 which was named MM (Table 4). Immunohistochemistry 
of B13 cells infected with R1 revealed relatively low reprogramming efficiency of this batch of 
Ad-PNM with 24% of cells Pdx1+ (Figure 5 & 6B). A dilution assay was performed with MM on 
B13 cells. Immunohistochemistry and quantification showed a higher reprogramming efficiency 
than R1 with 86% of cells Pdx1+ and approximately 70% also positive for insulin expression 
(Figure 6A & B).  The MM Ad-PNM dilution assay revealed Pdx1 and insulin expression 
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decreased when the infection titer of the virus decreased (Figure 6C). 
Figure 5. Type 2 diabetic NHP Ad-PNM infection functional assay. To test the infection 
efficiency of the Ad-PNM batch administered to the type 2 diabetic NHP, B13 cells were plated at  
a density of 50,000 cells/9.6 cm2, infected with Ad-PNM and incubated for three days. The cells 
were fixed and immunocytochemistry was performed to visualize reprogramming events. Scale 
bar is 100 µm. Insulin (red), Pdx1 (green), DAPI (blue).
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Figure 6A. Type 1 diabetic NHP Ad-PNM infection functional assay. The Ad-PNM batch infused 
into the type 1 diabetic NHP was tested for functionality at different dilutions. B13 cells were 
plated in 6-well plates, infected, and incubated for three days before being fixed. Reprogramming  
events were visualized by immunocytochemistry for Pdx1 (green) and Insulin (red). DAPI (blue) 
was used for counting cells. Scale bar is 100 µm. 
Figure 6B. Percent of B13 cells Pdx1+ and Pdx1+/Ins+ for Ad-PNM batches made for the type 1  
and 2 diabetic NHP portal vein infusions. At least three fields were counted from 200x 
magnification similar to those in Figures 5 & 6A.
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Figure 6C. Percent of B13 cells Pdx1+ and Pdx1+/Ins+ for MM Ad-PNM made for the type 1 
diabetic NHP portal vein infusion. At least three fields were counted from 200x magnification 
similar to those in Figure 6A.
Plaque forming units assay
Multiple attempts were made to conduct a plaque forming units assay to titer the virus in 
MM Ad-PNM that was infused into the type 1 diabetic NHP. With each attempt, the cultures 
were contaminated by mold growth before the 12-21 day time point for plaque formation was 
reached.
Type 2 diabetic NHP Ad-PNM infusion
After analysis of Ad-PNM, it was administered in vivo through portal vein catheter to 
NHP's. The infusion of 5mL of R1 Ad-PNM into the type 2 diabetic NHP, an 18 year old, 
32
4.14x10^9 2.07x10^10 4.14x10^10
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
100.00%
Type 1 diabetic NHP Ad-PNM infection Functional Assay on B13's
%Pdx1+
%Pdx1+/Ins+
Virus Titer (ifu/mL)
P
er
ce
nt
 e
xp
re
ss
io
n
cynomolgus macaque weighing 8.5kg was to test the safety and efficacy of Ad-PNM to treat 
diabetes in a large animal model. Since this NHP was a type 2 diabetic, his islets produced insulin 
but his muscle and adipose tissue had developed a resistance to insulin leading to a loss of 
glycemic control. Exogenous insulin was administered to control blood glucose levels that were 
monitored twice a day (Figure 6D). No adverse effects were observed. Ad-PNM was detected in 
needle biopsies from the type 2 diabetic NHP liver at three and nine days after infusion (see 
previous Figure 2). At the time of the type 2 diabetic NHP's necropsy, three one-inch by one-inch 
liver pieces were obtained. Some of this tissue was prepared for immunocytochemistry and the 
remaining tissue was digested to isolate bile duct cells. 
Figure 6D. Type 2 diabetic NHP blood glucose. 
In vitro   NHP bile duct cells 
After isolating bile duct cells from the type 2 diabetic NHP liver, three different plating 
conditions were used. Some of the bile duct cells were plated either in or on type I collagen and 
kept in culture for 21 days to observe for cell expansion. Both culture conditions were tested for 
expression of Sox9 protein, a bile duct cell marker. Cells in collagen were passaged (P1) from the 
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collagen, split 1:2, and plated on tissue-culture treated plastic. One of the P1 in collagen bile duct 
cell wells was infected with A2 Ad-PNM and kept in culture an additional three days. The other 
well of P1 in collagen bile duct cells was fixed fro imunnohistochemistry the day after passaging. 
Bile duct cells on collagen were fixed without passaging. Cells plated in and on collagen had 
Sox9 expressing cells (Figure 7A). The P1 in collagen bile duct cells infected with A2 Ad-PNM 
were fixed and tested for Pdx1 expression after three days in culture (Bottom row of Figure 7A). 
Ad-PNM infected and uninfected NHP bile duct cells cultured in collagen were counted to 
quantify the percent expression of either Sox9+ or Pdx1+ cells (Figure 7B).
Figure 7A. In vitro type 2 diabetic NHP bile duct cells cultured with type I collagen. Cells 
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isolated from NHP liver expressed Sox9. These cells also have the capacity to be infected with 
Ad-PNM in vitro since Pdx1 was expressed in some of the bile duct cells after administration of 
Ad-PNM. Scale bar 100 µm.
Figure 7B. Percent expression of Pdx1 or Sox9 in NHP bile duct cells after in vitro culture in 
collagen. At least three 200x magnification fields were counted similar to those in Figure 7A.
Another fraction of the isolated NHP bile duct cells were plated directly on tissue-culture 
treated plastic plates. This fraction was divided into three sub-populations of cells that were i) 
uninfected, cultured for four days, ii) infected with A2 Ad-PNM, cultured for four days, and iii)  
infected with A2 Ad-PNM, cultured for ten days. Each sub-population was fixed and tested for 
Pdx1 and insulin expression. The uninfected population had no expression of Pdx1 or insulin 
(data not shown). The infected population cultured for four days had robust Pdx1 and insulin 
expression (Left column of Figure 8). However, the infected population cultured for ten days had 
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no insulin expression but retained Pdx1 expression (Right column of Figure 8). 
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Figure 8. Ad-PNM infection of NHP bile duct cells. Type 2 diabetic NHP bile duct cells infected 
in vitro with Ad-PNM express insulin and Pdx1 after four days in culture. After 10 days in 
culture, Pdx1 expression is still evident but no insulin expression is detected. ICM images are 
provided to give context to cell morphology. Scale bars 100µm.
Type 1 diabetic NHP Ad-PNM infusion
The type 1 diabetic NHP was a 5 year and 8 month old cynomolgus macaque weighing 
about 5.5kg. To simulate type 1 diabetes in this NHP, STZ had been administered to ablate 
pancreatic islets and thus cease all endogenous insulin production48. When the type 1 diabetic 
NHP was made exogenous insulin dependent, blood glucose readings were taken in the morning 
and evening throughout the study (Figure 9A). Seven days prior to MM Ad-PNM infusion, two 
needle biopsies from Thresh's liver were taken for mRNA expression analysis (Figure 9B).  The 
WT NHP lane was an unrelated, non-diabetic control liver sample and was not expected to have 
products for Ad-PNM^Pdx1, Ad-PNM^MafA, or human insulin. However, we did expect to see a 
band for albumin since the mRNA was from liver tissue. No Ad-PNM transcripts or insulin 
mRNA expression were seen in the day -7 sample from the type 1 diabetic NHP. Gapdh 
expression was used as a control for the PCR reaction for all samples. Positive (+ve) and negative 
(-ve) control samples are in the right two lanes. Human islet cDNA was used as a positive control 
sample for the insulin primer and cDNA from B13 cells infected with Ad-PNM was used as 
positive controls for the mouse Pdx1 and Mafa primers. No cDNA template was added to the 
PCR reactions for negative controls (Figure 9B).
On day zero, a total of 6mL of MM Ad-PNM was administered to the type 1 diabetic NHP 
through his portal vein catheter. In anticipation of insulin production from transiently respecified 
hepatocytes, the administration of exogenous insulin was reduced. At day 3, two needle biopsies 
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from Thresh's liver were collected. mRNA was extracted from the biopsies and cDNA prepared 
to test for Ad-PNM transcripts as well as insulin mRNA expression. The day +3 samples 
indicated expression of Ad-PNM^Pdx1, Ad-PNM^MafA and insulin. Detection of Ad-PNM 
transcripts meant the infusion into the liver was successful and the exogenous gene expression 
had remained in the liver for three days. Detection of insulin mRNA at +3days suggests some 
cells in the liver were respecified by Ad-PNM and had began to express insulin (Figure 9B). At 
day 3, an adverse event occurred in which the type 1 diabetic NHP developed ketones (see 
BETA-HYDROXYBUTYRATE{BHY} pathology: 1.40 mmol/L in Appendix) because 
endogenous insulin expression from cells reprogrammed by Ad-PNM as well as exogenous 
insulin administration was not sufficient to stimulate glucose transport into cells. The PCRC 
addressed the event by increasing exogenous insulin levels and administering intravenous saline. 
Two needle biopsies of the type 1 diabetic NHP liver were collected on day +10 for mRNA 
extraction and cDNA preparation to test for Ad-PNM and insulin expression. By this time point 
no Ad-PNM^Pdx1, Ad-PNM^MafA, or insulin mRNA expression was detected (Figure 9B). Two 
different reasons could account for the absence of gene expression. First, the needle biopsies may 
not have collected liver tissue that was exposed to Ad-PNM. Second, expression of Ad-PNM had 
been transient and cleared from the liver. In conclusion, Ad-PNM was successfully infused into 
the liver of a NHP and insulin expression was detected. The type 1 diabetic NHP was euthanized 
35 days after infusion. Final mRNA expression has not been prepared. 
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Figure 9A. Type 1 diabetic NHP blood glucose levels. The blue line indicates morning blood 
glucose levels and the red line evening blood glucose levels. The upper and lower yellow 
horizontal lines indicate the average range (47-72 mg/dL) of blood glucose numbers for wild type  
cynomolgus macaques55.
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Figure 9B. Type 1 diabetic NHP qualitative cDNA expression.
Identifying ductal cells in the liver and pancreas
Since NHP or human liver samples were not available on a regular basis, human pancreatic 
ducts were characterized. Frozen sections of NHP liver, human liver, and human pancreas were 
prepared and tested for Sox9 protein expression.  All three tissues have Sox9+ cells lining the 
ducts (Figure 10). Cytokeratin 19 is an intermediate filament specific to epithelial ductal cells and 
is co-localized with Sox9+ cells in NHP liver and human liver sections. Rhodamine labeled 
Concanavalin A (Con A), gave context to the acinar tissue around the human pancreatic ducts 
stained with Sox9  (Figure 10). A common cell population that is Sox9+ was found in liver bile 
ducts and pancreas ducts. Human pancreatic tissue was readily available after islet isolation for 
IAT. 
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Figure 10. Sections of NHP liver, human liver, and human pancreas showing Sox9+ ductal cells. 
 50μm scale bars
Following human islet autotransplantation, isolation of pancreatic duct cells from the unused 
tissue was performed to assess for cell expansion and ability for Ad-PNM reprogramming into an 
insulin-secreting cell type.
Isolation of human pancreatic ductal cells
Fifteen patients underwent TP-IAT procedures through the University of Minnesota's 
Medical Center. Following each islet-isolation, pancreas tissue not used for transplant was stored 
in UW solution at 4°C. When samples arrived in the laboratory, they were visually assessed to 
remove undesired sutures or fibrotic tissue. Each sample varied in total volume and digestion 
following islet-isolation (Figure 11). The variation among samples may contribute to the success 
of epithelial cell isolation (Table 5). 
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Table 5. Post-islet isolation samples.
Patient ID Successful Epithelial Ball 
Isolation
1-6/20/2014 Yes
2-6/30/2014 No
3-7/7/2014 Yes
4-7/11/2014 Yes
5-7/14/2014 No
6-7/18/2014 Yes
7-7/21/2014 Yes
8-8/11/2014 No
9-8/18/2014 Yes
10-8/22/2014 No
11-8/25/2014 No
12-8/29/2014 Yes
13-9/29/2014 No
14-10/13/2014 Yes
15-10/27/2014 Yes
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Figure 11. Human pancreatic tissue after islet-isolation. Images of samples 1-15 after TP-IAT in 
10cm dishes. Part of a human pancreas not put through an islet-isolation protocol is pictured for 
comparison.
The digestion and isolation protocol was gradually refined with each sample to the point 
where clean epithelial cell aggregates were formed (Figure 12). Immunohistochemistry detecting 
Sox9 and Ck19 in cells in adherent culture indicated that the epithelial cell aggregates contained 
ductal cells. The co-localization of Sox9 and Ck19 in cells isolated from the first patient is shown 
in Figure 13. 
43
Figure 12. Isolated human pancreatic ductal epithelial cell aggregates. Phase contrast picture of  
human pancreatic ductal epithelial cells in suspension from the 6th patient. Scale bar is 500µm. 
Figure 13. Pancreatic ductal cells from the 1st human patient sample. Epithelial ductal cells were  
successfully isolated from human post-islet isolation pancreas tissue. Sox9/Ck19 double positive 
cells were detected. 100μm scale bar.
Reprogramming human pancreatic ductal cells
After confirming the protocol isolated pancreatic ductal cells, the reprogramming of this 
cell type was attempted. The epithelial cell aggregates were lightly trypsinized, divided into two 
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sub-populations, and plated on Biocoat plates with collagen coating. One population was infected 
with A8 Ad-PNM while the other remained uninfected. Some epithelial aggregates and single 
cells adhered in each sub-population, but the majority failed to adhere to the plate. After four 
days in culture, attached cells were fixed. The uninfected population had no Pdx1 or insulin
 expression. The infected population had many Pdx1+ cells (Large picture in Figure 14) and 
scattered had insulin+ cells (Right inset in Figure 14).  The cell type that expressed Pdx1 also 
expressed Ck19, which suggests Ad-PNM infected ductal cells (Left inset in Figure 14). 
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Figure 14. Ad-PNM infection of human pancreatic ductal cells. In the large picture Pdx1+ cells 
from the fifteenth patient are shown after Ad-PNM infection and four days of culture. 
Insulin/Pdx1 double positive cells can be seen in the right inset picture. 100µm scale bar in large  
figure. 50µm scale bar in insets. 
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Discussion
This research showed Ad-PNM can be delivered safely and effectively in a large NHP 
animal model. In the experiment with Thresh Ad-PNM transcripts and insulin expression were 
detected in the liver which was the targeted tissue. It was also shown that Sox9+ cells were found 
in bile ducts of the liver and ducts in the pancreas. Ad-PNM can infect human pancreatic ductal 
cells isolated from pancreatic tissue discarded after islet isolation. 
The next phase of the work with the NHP large animal model would include portal vein 
infusion of Ad-PNM and an additional treatment to attempt to enhance reprogramming within the 
liver. Past research in the Dutton Laboratory has shown a peroxisome-proliferator-activated 
receptor (PPAR) agonist, WY14643, also known as pirinixic acid, will cause cell proliferation 
and enhance direct reprogramming in mouse livers when administered through the GI tract two 
days prior and two days post Ad-PNM infusion through the tail vein25. It would be expected that 
administering WY14643 in a similar manner as the mice, to an STZ treated NHP and infusing a 
greater volume of Ad-PNM may reprogram more hepatocytes initially but also reprogram bile 
ducts into stable insulin-secreting structures. The direct reprogramming to insulin-secreting ducts 
may provide enough insulin expression to be clinically relevant if sufficient C-peptide levels are 
attained. Another avenue to improve reprogramming would involve searching for more and/or 
other transcription factors to promote the Sox9+ cells to become more β-cell-like. 
Further work on reprogramming human pancreatic ductal cells is necessary for their 
clinical translation. Improvement in reprogramming with other transcription factors could help as 
well as optimizing culture conditions. Once reprogramming efficiency was improved, STZ nude 
mice would be used for transplantation of the human pancreatic ductal cells under the kidney 
capsule to see if diabetes in a small animal model could be rescued. An expansion phase would 
also be needed to generate enough cells for reprogramming to produce enough insulin to be 
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clinically relevant and transplanted in a similar manner as islets or encapsulated and placed in the 
body. Human pancreatic ductal cells may also be a good source to make iPSCs with the intention 
of differentiating the pluripotent cells into β-cells with a protocol like the one found in3. The 
epigenetics of the pancreatic ductal cells may retain epigenetic memory from the pancreatic 
lineage when iPSCs are generated56 and these iPSCs may differentiate more readily into 
pancreatic progenitors and ultimately β-cells than iPS cell lines derived from other tissues. 
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